Switch of serotonergic descending inhibition into facilitation by a spinal chloride imbalance in neuropathic pain.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
29 Jul 2022
Historique:
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 28 7 2022
Statut: ppublish

Résumé

Descending control from the brain to the spinal cord shapes our pain experience, ranging from powerful analgesia to extreme sensitivity. Increasing evidence from both preclinical and clinical studies points to an imbalance toward descending facilitation as a substrate of pathological pain, but the underlying mechanisms remain unknown. We used an optogenetic approach to manipulate serotonin (5-HT) neurons of the nucleus raphe magnus that project to the dorsal horn of the spinal cord. We found that 5-HT neurons exert an analgesic action in naïve mice that becomes proalgesic in an experimental model of neuropathic pain. We show that spinal KCC2 hypofunction turns this descending inhibitory control into paradoxical facilitation; KCC2 enhancers restored 5-HT-mediated descending inhibition and analgesia. Last, combining selective serotonin reuptake inhibitors (SSRIs) with a KCC2 enhancer yields effective analgesia against nerve injury-induced pain hypersensitivity. This uncovers a previously unidentified therapeutic path for SSRIs against neuropathic pain.

Identifiants

pubmed: 35895817
doi: 10.1126/sciadv.abo0689
pmc: PMC9328683
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eabo0689

Références

Neuroscience. 2009 Mar 3;159(1):316-24
pubmed: 19141313
Prog Neurobiol. 2002 Apr;66(6):355-474
pubmed: 12034378
Nat Rev Neurosci. 2004 Jul;5(7):565-75
pubmed: 15208698
J Pharmacol Exp Ther. 2007 Jun;321(3):1046-53
pubmed: 17329553
Curr Opin Support Palliat Care. 2016 Jun;10(2):143-8
pubmed: 27043287
Nat Commun. 2018 May 14;9(1):1886
pubmed: 29760484
Pain. 2005 Mar;114(1-2):295-302
pubmed: 15733656
Pain. 2013 May;154(5):647-659
pubmed: 23142143
Lancet Neurol. 2015 Feb;14(2):162-73
pubmed: 25575710
Mol Pain. 2012 Aug 20;8:58
pubmed: 22906126
Nature. 2003 Aug 21;424(6951):938-42
pubmed: 12931188
Mol Pain. 2014 Nov 19;10:70
pubmed: 25410898
Pain. 2005 Dec 5;118(3):289-305
pubmed: 16213659
J Clin Invest. 2010 Nov;120(11):3779-87
pubmed: 21041960
Cell Rep. 2016 Nov 1;17(6):1699-1710
pubmed: 27806306
Neuroscience. 2016 Dec 3;338:183-206
pubmed: 27401055
Pain. 2004 Mar;108(1-2):163-9
pubmed: 15109520
Prog Neurobiol. 2009 Jul;88(3):184-202
pubmed: 19393288
Pain. 2005 Oct;117(3):292-303
pubmed: 16150546
Exp Neurol. 2018 Aug;306:105-116
pubmed: 29729247
Cell. 2018 Sep 6;174(6):1599
pubmed: 30193115
PLoS One. 2012;7(4):e35293
pubmed: 22558137
Nat Neurosci. 2019 Oct;22(10):1659-1668
pubmed: 31501573
Pain. 2016 Aug;157(8):1704-1710
pubmed: 27045524
Mol Pain. 2018 Jan-Dec;14:1744806917749683
pubmed: 29212409
Pain. 2000 Aug;87(2):149-158
pubmed: 10924808
Cell. 2015 Oct 8;163(2):301-12
pubmed: 26451482
Trends Pharmacol Sci. 2004 Dec;25(12):613-7
pubmed: 15530638
Brain Res. 1993 Apr 2;607(1-2):89-98
pubmed: 7683245
Nat Med. 2013 Nov;19(11):1524-8
pubmed: 24097188
Front Cell Neurosci. 2016 Aug 03;10:195
pubmed: 27536220
Brain Res. 1980 Aug 4;194(2):377-89
pubmed: 6155975
Nature. 2005 Dec 15;438(7070):1017-21
pubmed: 16355225
Annu Rev Neurosci. 1984;7:309-38
pubmed: 6143527
Mol Pain. 2014 Apr 16;10:26
pubmed: 24739328
J Neurosci. 2014 Jun 11;34(24):8300-17
pubmed: 24920633
Neuron. 2017 Feb 22;93(4):822-839.e6
pubmed: 28162807
Nat Commun. 2019 Feb 28;10(1):983
pubmed: 30816113
Pain. 1975 Jun;1(2):139-145
pubmed: 1088446
Brain Res. 1993 Jul 30;618(1):95-108
pubmed: 8402183
Nat Neurosci. 2020 Nov;23(11):1376-1387
pubmed: 33020652
J Pharmacol Sci. 2006 Jun;101(2):107-17
pubmed: 16766858
Cell Rep. 2019 Jul 16;28(3):590-596.e4
pubmed: 31315039
Neurochem Int. 2019 Mar;124:245-255
pubmed: 30685320
Somatosens Mot Res. 1992;9(2):157-73
pubmed: 1354402
Brain Res. 2004 Sep 3;1019(1-2):68-76
pubmed: 15306240
Brain. 2014 Mar;137(Pt 3):724-38
pubmed: 24369380
Neuroimage. 2016 Jan 1;124(Pt A):54-62
pubmed: 26343321
Nature. 2016 Jun 01;534(7606):206-12
pubmed: 27279213
Prog Neurobiol. 2014 Oct;121:1-18
pubmed: 25010858
Curr Opin Neurobiol. 2014 Dec;29:159-64
pubmed: 25064178
Front Neural Circuits. 2014 Jul 04;8:77
pubmed: 25071458
Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16472-7
pubmed: 16251278
Curr Neuropharmacol. 2018 Jan 30;16(2):210-221
pubmed: 28901281
Curr Opin Support Palliat Care. 2014 Jun;8(2):143-51
pubmed: 24752199
Nat Neurosci. 2012 Jul 26;15(8):1068-73
pubmed: 22837036
Pain. 2001 Feb 1;90(1-2):173-9
pubmed: 11166984
Neuron. 2016 Mar 16;89(6):1157-1172
pubmed: 26985723
Brain. 2019 Jun 1;142(6):1535-1546
pubmed: 31135041
Pain. 2015 Apr;156 Suppl 1:S24-S31
pubmed: 25789433
IBRO Rep. 2017 Apr 09;2:72-80
pubmed: 30135935
Curr Opin Physiol. 2019 Oct;11:109-115
pubmed: 32864531

Auteurs

Franck Aby (F)

Université de Bordeaux, Bordeaux, France.
Institut des maladies neurodégénératives (IMN), CNRS UMR 5293, Bordeaux, France.

Louis-Etienne Lorenzo (LE)

CERVO Brain Research Center, Université Laval, Québec City, Canada.
Department of Psychiatry and Neuroscience, Université Laval, Québec City, Canada.

Zoé Grivet (Z)

Université de Bordeaux, Bordeaux, France.
Institut des maladies neurodégénératives (IMN), CNRS UMR 5293, Bordeaux, France.

Rabia Bouali-Benazzouz (R)

Université de Bordeaux, Bordeaux, France.
Institut des maladies neurodégénératives (IMN), CNRS UMR 5293, Bordeaux, France.

Hugo Martin (H)

NutriNeuro, UMR, INRAe, 1286 Bordeaux, France.

Stéphane Valerio (S)

Aquineuro, SA, Bordeaux, France.

Sara Whitestone (S)

Université de Bordeaux, Bordeaux, France.
Institut des maladies neurodégénératives (IMN), CNRS UMR 5293, Bordeaux, France.

Dominique Isabel (D)

CERVO Brain Research Center, Université Laval, Québec City, Canada.
Department of Psychiatry and Neuroscience, Université Laval, Québec City, Canada.

Walid Idi (W)

Université de Bordeaux, Bordeaux, France.
Institut des maladies neurodégénératives (IMN), CNRS UMR 5293, Bordeaux, France.

Otmane Bouchatta (O)

Université de Bordeaux, Bordeaux, France.
Institut des maladies neurodégénératives (IMN), CNRS UMR 5293, Bordeaux, France.
CERVO Brain Research Center, Université Laval, Québec City, Canada.
Department of Psychiatry and Neuroscience, Université Laval, Québec City, Canada.
NutriNeuro, UMR, INRAe, 1286 Bordeaux, France.
Aquineuro, SA, Bordeaux, France.
Université Cadi Ayyad, Marrakech, Morocco.

Philippe De Deurwaerdere (P)

Université de Bordeaux, Bordeaux, France.
Institut des neurosciences cognitives et intégratives d'aquitaine (INCIA) CNRS UMR 5287, Bordeaux, France.

Antoine G Godin (AG)

CERVO Brain Research Center, Université Laval, Québec City, Canada.
Department of Psychiatry and Neuroscience, Université Laval, Québec City, Canada.

Cyril Herry (C)

Neurocentre Magendie, INSERM, U862, Bordeaux, France.

Xavier Fioramonti (X)

NutriNeuro, UMR, INRAe, 1286 Bordeaux, France.

Marc Landry (M)

Université de Bordeaux, Bordeaux, France.
Institut des maladies neurodégénératives (IMN), CNRS UMR 5293, Bordeaux, France.

Yves De Koninck (Y)

CERVO Brain Research Center, Université Laval, Québec City, Canada.
Department of Psychiatry and Neuroscience, Université Laval, Québec City, Canada.

Pascal Fossat (P)

Université de Bordeaux, Bordeaux, France.
Institut des maladies neurodégénératives (IMN), CNRS UMR 5293, Bordeaux, France.

Classifications MeSH